Jennifer Chien
Corporate Officer/Principal chez RHYTHM PHARMACEUTICALS, INC.
Fortune : 296 897 $ au 31/03/2024
Profil
Jennifer L.
Chien is currently the Executive Vice President & Head-North America at Rhythm Pharmaceuticals, Inc. Prior to this, she worked as the Vice President & Head-Genetic Diseases at Genzyme Therapeutics Ltd.
from 2017 to 2020.
She also briefly served as the Chief Commercial Officer at Krystal Biotech, Inc. in 2020.
Ms. Chien received her graduate degree from Harvard University and her undergraduate degree from Massachusetts Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/03/2024 | 6 852 ( 0,01% ) | 296 897 $ | 31/03/2024 |
Postes actifs de Jennifer Chien
| Sociétés | Poste | Début |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 09/11/2020 |
Anciens postes connus de Jennifer Chien
| Sociétés | Poste | Fin |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Corporate Officer/Principal | 16/10/2020 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01/01/2020 |
Formation de Jennifer Chien
| Harvard University | Graduate Degree |
| Massachusetts Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| KRYSTAL BIOTECH, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
